The global hyperlipidemia drugs market size is calculated at USD 22.93 billion in 2024, grew to USD 23.85 billion in 2025, and is predicted to hit around USD 33.94 billion by 2034, poised to grow at a CAGR of 4% between 2024 and 2034. The Europe hyperlipidemia drugs market size accounted for USD 10.32 billion in 2024 and is anticipated to grow at the fastest CAGR of 3.99% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Hyperlipidemia Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Hyperlipidemia Drugs Market Revenue and Volume, by Drug Class, 2024-2034
8.1.1. Statins
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Bile Acid Sequestrants
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Cholesterol Absorption Inhibitors
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Fibric Acid Derivatives
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
8.1.5. PCSK9 Inhibitors
8.1.5.1. Market Revenue and Volume Forecast (2021-2034)
8.1.6. Combination
8.1.6.1. Market Revenue and Volume Forecast (2021-2034)
8.1.7. Miscellaneous
8.1.7.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Hyperlipidemia Drugs Market Revenue and Volume, by Route of Administration, 2024-2034
9.1.1. Oral
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Parenteral
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.1.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
11.1. F. Hoffmann-La Roche Ltd. (Switzerland)
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Mylan N.V. (U.S.)
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Teva Pharmaceutical Industries Ltd. (Israel)
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Sanofi (France)
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Pfizer Inc. (U.S.)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. GlaxoSmithKline plc (UK)
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Novartis AG (Switzerland)
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. AstraZeneca (U.K.)
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Johnson & Johnson Private Limited (U.S.)
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Sun Pharmaceutical Industries Ltd. (India)
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample